This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
GLP-1 Drugs Cut Risk of Alzheimer's, NVO & LLY Shares Rise
by Ahan Chakraborty
Shares of Novo Nordisk and Eli Lilly gain following study results that show GLP-1 drugs cut the risk of heart and kidney diseases as well certain brain ailments.
Viking Therapeutics, Inc. (VKTX) Increases Yet Falls Behind Market: What Investors Need to Know
by Zacks Equity Research
In the closing of the recent trading day, Viking Therapeutics, Inc. (VKTX) stood at $32.87, denoting a +0.67% change from the preceding trading day.
Is It Worth Investing in Viking Therapeutics (VKTX) Based on Wall Street's Bullish Views?
by Zacks Equity Research
The average brokerage recommendation (ABR) for Viking Therapeutics (VKTX) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
NVO, VKTX Stocks Fall as Lilly's Zepbound, Mounjaro Sales Slow Down
by Sundeep Ganoria
Shares of several obesity drugmakers dip after LLY lowered its revenue outlook for 2024 amid slower-than-expected sales growth of its tirzepatide products in Q4.
LLY Stock Down on Lower-Than-Expected Sales Guidance for Q4
by Zacks Equity Research
LLY's shares slip more than 6% as it cuts outlook for 2024 sales. Preliminary fourth-quarter revenues fall short of estimates.
Viking Therapeutics, Inc. (VKTX) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Viking Therapeutics, Inc. (VKTX) closed at $38.88, marking a -1.09% move from the previous day.
LLY Falls Around 14% in 3 Months: How to Play the Stock
by Kinjel Shah
Though Eli Lilly stock looks quite expensive, we suggest investors hold on to it as it still has robust growth prospects.
Viking Therapeutics Starts Mid-Stage Study on Oral Weight-Loss Drug
by Zacks Equity Research
The initiation of the phase 2 study is based on early-stage data, which show that patients who received VKTX's obesity pill lost up to 8.2% in body weight after 28 days.
Viking Therapeutics, Inc. (VKTX) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Viking Therapeutics, Inc. (VKTX) closed at $42.53, marking a -0.84% move from the previous day.
Is Viking Therapeutics (VKTX) a Buy as Wall Street Analysts Look Optimistic?
by Zacks Equity Research
The average brokerage recommendation (ABR) for Viking Therapeutics (VKTX) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
VKTX Stock Loses More Than 20% in Six Months: Should You Buy the Dip?
by Sundeep Ganoria
Despite the rising competition in the obesity space, we believe that there is room for smaller biotechs like Viking Therapeutics to grab a share of this booming market.
Viking Therapeutics, Inc. (VKTX) Advances While Market Declines: Some Information for Investors
by Zacks Equity Research
In the most recent trading session, Viking Therapeutics, Inc. (VKTX) closed at $40.25, indicating a +1.19% shift from the previous trading day.
Viking Therapeutics, Inc. (VKTX) Gains As Market Dips: What You Should Know
by Zacks Equity Research
The latest trading day saw Viking Therapeutics, Inc. (VKTX) settling at $42.68, representing a +0.78% change from its previous close.
Novo Nordisk Stock Plunges 18% in a Week: What Should Investors Do?
by Ahan Chakraborty
NVO stock declines after a recent obesity study setback and intense competition from market rivals but offers long-term growth potential.
Lilly's Zepbound Receives FDA Approval for Sleep Apnea
by Zacks Equity Research
FDA approves LLY's obesity drug Zepbound for its second indication, moderate-to-severe obstructive sleep apnea.
Viking Therapeutics, Inc. (VKTX) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Viking Therapeutics, Inc. (VKTX) closed at $42.25, marking a +1.83% move from the previous day.
Merck Enters Obesity Space, Buys Rights to Hansoh's Oral GLP-1 Drug
by Zacks Equity Research
Merck gets exclusive global rights to develop, manufacture and commercialize GLP-1 receptor agonist, HS-10535, from Hansoh Pharma.
Here's Why VKTX Stock Plummeted 18% on Wednesday
by Zacks Equity Research
The selloff in Viking Therapeutics stock comes after some investors raised concerns for the small biotech amid Merck's entry into the obesity space.
Viking Therapeutics, Inc. (VKTX) Stock Moves -1.75%: What You Should Know
by Zacks Equity Research
Viking Therapeutics, Inc. (VKTX) closed at $47.03 in the latest trading session, marking a -1.75% move from the prior day.
The Zacks Analyst Blog Eli Lilly, Novo Nordisk's Amgen and Viking Therapeutics
by Zacks Equity Research
Eli Lilly, Novo Nordisk's Amgen and Viking Therapeutics are included in this Analyst Blog.
Eli Lilly to Invest $3B in Wisconsin Plant to Meet Obesity Drug Demand
by Zacks Equity Research
Per Lilly, this is its single-largest manufacturing investment in the country outside its home state. It plans to start construction on the expansion next year.
How to Play LLY Stock as Zepbound Beats NVO's Wegovy in Obesity Study
by Kinjel Shah
The latest Zepbound data bodes well for Lilly and could help establish the drug as the new standard for obesity medications.
LLY's Zepbound Outshines NVO's Wegovy in Head-to-Head Obesity Study
by Zacks Equity Research
LLY's obesity drug, Zepbound, shows an average weight loss of 20.2%, superior to 13.7% for NVO's Wegovy in a head-to-head study.
AMGN Stock Down Despite Strong Data From Obesity Drug Study
by Zacks Equity Research
Data from a phase II study shows that AMGN's obesity drug MariTide leads to sustainable weight loss, robust improvements in cardiometabolic parameters and strong HbA1c reduction.
LLY, NVO Stock Up as Biden Proposes Medicare Cover for Obesity Drugs
by Kinjel Shah
The Biden administration believes that including obesity drugs in Medicare coverage will reduce out-of-pocket costs for the drugs and make them affordable.